Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells $145,918.85 in Stock

Posted by Geri Gentry on Jun 25th, 2026

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) major shareholder Ra Capital Management, L.P. sold 416,911 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $0.35, for a total transaction of $145,918.85. Following the transaction, the insider directly owned 303,719 shares in the company, valued at approximately $106,301.65. This trade represents a 57.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

On Tuesday, June 16th, Ra Capital Management, L.P. sold 149,625 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total value of $55,361.25.
On Monday, June 15th, Ra Capital Management, L.P. sold 128,770 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.39, for a total value of $50,220.30.
On Friday, June 12th, Ra Capital Management, L.P. sold 170,441 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.40, for a total value of $68,176.40.
On Thursday, June 11th, Ra Capital Management, L.P. sold 262,503 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.38, for a total value of $99,751.14.
On Wednesday, June 10th, Ra Capital Management, L.P. sold 45,923 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total transaction of $16,991.51.
On Tuesday, June 9th, Ra Capital Management, L.P. sold 369,800 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total transaction of $136,826.00.
On Tuesday, May 12th, Ra Capital Management, L.P. sold 101,151 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total transaction of $64,736.64.
On Monday, May 11th, Ra Capital Management, L.P. sold 87,490 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.67, for a total transaction of $58,618.30.
On Friday, May 8th, Ra Capital Management, L.P. sold 376,526 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.71, for a total value of $267,333.46.

Werewolf Therapeutics Trading Up 3.6%

HOWL opened at $0.37 on Thursday. The firm has a market cap of $18.21 million, a price-to-earnings ratio of -0.30 and a beta of 0.29. Werewolf Therapeutics, Inc. has a 12 month low of $0.34 and a 12 month high of $2.38. The stock has a fifty day moving average price of $0.56 and a 200-day moving average price of $0.68.

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. On average, equities research analysts forecast that Werewolf Therapeutics, Inc. will post -1.08 EPS for the current year.

Institutional Trading of Werewolf Therapeutics

Several large investors have recently bought and sold shares of the stock. Jane Street Group LLC acquired a new position in Werewolf Therapeutics during the 2nd quarter valued at approximately $409,000. Renaissance Technologies LLC grew its holdings in shares of Werewolf Therapeutics by 48.6% during the fourth quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock valued at $429,000 after buying an additional 221,766 shares during the last quarter. Citadel Advisors LLC purchased a new stake in shares of Werewolf Therapeutics during the third quarter valued at $304,000. Vanguard Group Inc. grew its holdings in shares of Werewolf Therapeutics by 8.5% during the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after buying an additional 109,796 shares during the last quarter. Finally, Marshall Wace LLP acquired a new position in shares of Werewolf Therapeutics in the 2nd quarter valued at $113,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Weiss Ratings lowered shares of Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 16th. Wall Street Zen downgraded shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Two research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $3.75.

Read Our Latest Stock Report on Werewolf Therapeutics

Werewolf Therapeutics Company Profile

(Get Free Report)

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.